- Home
- » Tags
- » Tofacitinib
Top View
- 15. COVID-19 Tedavisinde IL-1, IL-6 Ve TNF-Α Anti-Sitokin Monoklonal Antikor Kullanımı Prof
- Real-World Comparative Effectiveness and Safety of Tofacitinib And
- E001214.Full.Pdf
- Standards, Perspektiven Und Grenzen Der Konservativen Therapie
- Stembook 2018.Pdf
- Benlysta® (Belimumab) Prior Authorization With
- Safety of Tofacitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) - Cardiovascular Endpoints
- Recent Biotherapies and Infections
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- Cimzia (Certolizumab Pegol) C10269-A
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Dissecting the Heterogeneity in T-Cell Mediated Inflammation In
- New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases
- RMD Commentary, JAK Kinase Inhibitors: a Preferred Alternative to TNF Inhibitors?
- Tofacitinib Citrate PATIENT FACT SHEET (Xeljanz and Xeljanz XR)
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases Or Other Immune-Mediated Diseases: a Systematic Review and Meta-Analysis Pablo A
- Coccidioidomycosis
- XELJANZ® Safety Review Recommendation Issued in the European Union
- Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: a Cohort Study
- WO 2017/120601 Al 13 July 2017 (13.07.2017) P O P C T
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Efficacy and Safety of Tofacitinib Following Inadequate Response to Conventional Synthetic Or Biologic Disease- Modifying Antirheumatic Drugs
- A Case of New-Onset Vitiligo in a Patient on Tofacitinib and Brief Review of Paradoxical Presentations with Other Novel Targeted Therapies
- JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
- Tofacitinib Safe and Effective in Renal Transplant Recipients the Oral Janus Kinase Inhibitor, Tofacitinib, Groups
- Safety of Anti- Rheumatic Drugs in Men Trying to Conceive: a Systematic Review and Analysis of Published Evidence
- COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
- Simponi -ARIZONA
- Long-Term Safety of Certolizumab Pegol in Rheumatoid Arthritis, Axial
- Identification of Tofacitinib, Filgotinib and Ruxolitinib on Experimental Sjögren’S Syndrome Model in Mice 1036
- Annrheumdis-2020-219699.Full.Pdf
- List of Selected Drugs
- Guidelines for ATC Classification and DDD Assignment 2021
- XELJANZ® (Tofacitinib) Tablets for Oral Administration
- Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease Pavine L
- Responses by Tofacitinib (CP-690,550) Kamran Ghoreschi, Michael I
- Promising Drug Delivery System
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Benlysta® (Belimumab Subcutaneous Injection)
- Hamid Reza Ravanbod Thesis
- Xeljanz; INN-Tofacitinib
- Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms
- An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis J.A
- 'Off-Label Use of Tofacitinib: a Potential Treatment Option for SAPHO
- Selective Jakinibs: Prospects in Inflammatory and Autoimmune
- Identifying Novel B-Cell Targets for Chronic Inflammatory Autoimmune Disease by Screening Of
- Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
- Xeljanz, INN-Tofacitinib Citrate
- Mediated Inflammatory Diseases with Janus Kinase Inhibitors
- Background Materials and Methods Results Aim And
- INN-Nimet 1 1.7.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara